
    
      60 patients of cirrhosis with Minimal Hepatic Encephalopathy (MHE) who fulfills the inclusion
      & exclusion criteria will be the part of study. Study patients will be divided in to two
      groups ( n=30 in each group).

      Group L patients will receive lactulose therapy while Group NL will receive placebo. After 3
      months , S.endotoxins , inflammatory mediators and MRS will be repeated in each group.
    
  